Project Name: Oxford Oral Systemic Anti-Cancer Therapy (SACT) project manager collaborative working

Project Summary: 

The CWP, through the development of a new role, Oral Systemic Anti-Cancer Therapy (SACT) Project Manager, aims to implement a programme of changes via a number of projects to the Trust’s oncology service. Ultimately, this will:

  • Create more efficient and effective Oral SACT pathways resulting in more patients in clinics, referrals seen more quickly, faster implementation of NICE TAGs, and release of consultant time​;
  • Result in a conservative estimate of 300 extra clinic slots per year that would be utilised by the project manager through streamlining workforce and expanding digital capacity;​
  • Lead to a reduction in triage and clinical nurse specialist (CNS) telephone calls
  • Lead to a reduction in unintended admissions.​

In order to achieve this strategy, the CWP will recruit a Band 7 Project Manager for 24 months. The total length of the CW Project will therefore be 30 months. This will accommodate 3 months at the start to recruit the Project Manager and 3 months at the end to write an outcomes report.

Expected Benefits: 

Anticipated Benefits for Patients:

  • Increased access to equitable and consistent and standardised care.
  • Single point of contact for patients receiving oral SACT to ensure more personalised care.
  • Increased access to education and information on oral SACT
  • Improved adherence and consequently improve patients' outcomes, supported by a personalised care plan.
  • Improved patient satisfaction and reduced waiting time (to access overbooked clinics).
  • Reduced patient in-person attendance.
  • Reduce unplanned medical reviews and admissions. 

Anticipated Benefits for the Organisation(s):

  • Increase the overall quality of care and improve equity of access to specialist care for patients on oral SACT requiring treatment initiation, evaluation, and monitoring.
  • Improved clinician experiences.
  • Maximise the capacity of each SACT clinic

Anticipated Benefits for Novartis:

  • Better understanding of overall HCP and patient needs
  • Optimal use of medicines in line with local/national guidance (including Novartis medicines) in appropriate patients.
  • Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation

Start Date & Duration: October 2025, for 30 months

FA-11545199 | November 2025